OBJECTIVE: Aneuploidy is an independent risk factor for forthcoming carcinogenesis in ulcerative colitis (UC). An inferior prognosis of patients with ulcerative colitis-associated colorectal cancer (UCC) compared with those with sporadic colorectal cancer (SCC) has been reported, but remains controversial. This prompted us to investigate if aneuploidy can be observed in UCCs as frequently as in their sporadic counterpart and if aneuploidy per se might be a driving feature of poor prognosis in UCC. BACKGROUND DATA: We obtained clinical follow-up for 257 SCC patients (average observation time 57 months) and 31 UCC patients (51 months). Touch preparation slides or tissue sections were prepared of all 288 carcinomas for ploidy analysis. METHODS: Ploidy status was assessed for 260 SCCs and 31 UCCs by image cytometry and correlated to clinical features. Survival data were analyzed using Kaplan-Meier estimates. RESULTS: Aneuploidy was detected in 74.6% of SCCs and in all 31 UCCs. Logistic regression analysis yielded age (odds ratio [OR], 1.05; 95% CI, 1.02-1.09; P = 0.003) and aneuploidy (OR, 4.07; 95% CI, 1.46-11.36; P = 0.007) as independent prognostic factors for R0-resected patients devoid of metastases. Diploid SCCs had a more favorable 5-year survival (88.2%) than aneuploid SCCs (69.0%) and UCCs (73.1%) (P = 0.074). CONCLUSIONS: UC-associated carcinomas presented aneuploidy at significantly higher frequency than sporadic colorectal carcinomas (P < 0.0006). UCCs and aneuploid SCCs share a similar prognosis inferior to that of diploid SCCs. Aneuploidy proved to be the strongest independent prognostic marker for R0-resected colorectal cancer patients overall.
OBJECTIVE:Aneuploidy is an independent risk factor for forthcoming carcinogenesis in ulcerative colitis (UC). An inferior prognosis of patients with ulcerative colitis-associated colorectal cancer (UCC) compared with those with sporadic colorectal cancer (SCC) has been reported, but remains controversial. This prompted us to investigate if aneuploidy can be observed in UCCs as frequently as in their sporadic counterpart and if aneuploidy per se might be a driving feature of poor prognosis in UCC. BACKGROUND DATA: We obtained clinical follow-up for 257 SCC patients (average observation time 57 months) and 31 UCC patients (51 months). Touch preparation slides or tissue sections were prepared of all 288 carcinomas for ploidy analysis. METHODS: Ploidy status was assessed for 260 SCCs and 31 UCCs by image cytometry and correlated to clinical features. Survival data were analyzed using Kaplan-Meier estimates. RESULTS:Aneuploidy was detected in 74.6% of SCCs and in all 31 UCCs. Logistic regression analysis yielded age (odds ratio [OR], 1.05; 95% CI, 1.02-1.09; P = 0.003) and aneuploidy (OR, 4.07; 95% CI, 1.46-11.36; P = 0.007) as independent prognostic factors for R0-resected patients devoid of metastases. Diploid SCCs had a more favorable 5-year survival (88.2%) than aneuploid SCCs (69.0%) and UCCs (73.1%) (P = 0.074). CONCLUSIONS: UC-associated carcinomas presented aneuploidy at significantly higher frequency than sporadic colorectal carcinomas (P < 0.0006). UCCs and aneuploid SCCs share a similar prognosis inferior to that of diploid SCCs. Aneuploidy proved to be the strongest independent prognostic marker for R0-resected colorectal cancerpatients overall.
Authors: Timo Gemoll; Jens K Habermann; Johanna Lahmann; Silke Szymczak; Caroline Lundgren; Nana K Bündgen; Thomas Jungbluth; Britta Nordström; Susanne Becker; Marta I Lomnytska; Hans-Peter Bruch; Andreas Ziegler; Ulf Hellman; Gert Auer; Uwe J Roblick; Hans Jörnvall Journal: Cell Mol Life Sci Date: 2011-07-08 Impact factor: 9.261
Authors: Martina Oberländer; Michael Linnebacher; Alexandra König; Valentina Bogoevska; Christiane Brodersen; Regina Kaatz; Mathias Krohn; Michael Hackmann; Josef Ingenerf; Jan Christoph; Sebastian Mate; Hans-Ulrich Prokosch; Emre F Yekebas; Christoph Thorns; Jürgen Büning; Friedrich Prall; Ria Uhlig; Uwe J Roblick; Jakob R Izbicki; Ernst Klar; Hans-Peter Bruch; Brigitte Vollmar; Jens K Habermann Journal: Langenbecks Arch Surg Date: 2013-01-08 Impact factor: 3.445
Authors: Timo Gemoll; Uwe J Roblick; Silke Szymczak; Till Braunschweig; Susanne Becker; Bernd-Wolfgang Igl; Hans-Peter Bruch; Andreas Ziegler; Ulf Hellman; Michael J Difilippantonio; Thomas Ried; Hans Jörnvall; Gert Auer; Jens K Habermann Journal: Cell Mol Life Sci Date: 2011-02-03 Impact factor: 9.261
Authors: Rüdiger Meyer; Tilman Laubert; Martin Sommer; Claudia Benecke; Hendrik Lehnert; Klaus Fellermann; Hans-Peter Bruch; Tobias Keck; Christoph Thorns; Jens K Habermann; Jürgen Büning Journal: Int J Colorectal Dis Date: 2015-04-26 Impact factor: 2.571
Authors: Marco Gerling; Kari Nousiainen; Sampsa Hautaniemi; Stefan Krüger; Britta Fritzsche; Nils Homann; Hans-Peter Bruch; Gert Auer; Uwe J Roblick; Thomas Ried; Jens K Habermann Journal: Inflamm Bowel Dis Date: 2013 Mar-Apr Impact factor: 5.325